Advances in chronic myeloid leukemia treatment, particularly regarding tyrosine kinase
inhibitors, mandate regular updating of concepts and management. A European …

From the laboratory perspective, effective management of patients with chronic myeloid
leukemia (CML) requires accurate diagnosis, assessment of prognostic markers, sequential …

Abstract Mutations in the Bcr-Abl kinase domain may cause, or contribute to, resistance to
tyrosine kinase inhibitors (TKIs) in chronic myeloid leukemia patients. Recommendations …

Purpose Nilotinib is a second-generation tyrosine kinase inhibitor indicated for the treatment
of patients with chronic myeloid leukemia (CML) in chronic phase (CP; CML-CP) and …

Dasatinib is a BCR-ABL inhibitor with 325-fold higher potency than imatinib against
unmutated BCR-ABL in vitro. Imatinib failure is commonly caused by BCR-ABL mutations …

In patients with chronic myeloid leukemia, BCR-ABL mutations contribute to resistance to
tyrosine kinase inhibitor therapy. We examined the occurrence of treatment-emergent …

Targeted therapies of chronic myeloid leukemia (CML) using tyrosine kinase inhibitors (TKI)
have profoundly changed the natural history of the disease with a major impact on survival …

The remarkable progress made in the treatment of chronic myeloid leukemia (CML) over the
past decade has been accompanied by steady improvements in our capacity to accurately …

We report a third-generation sequencing assay on nanopore technology (MinION) for
detecting BCR-ABL1 KD mutations and compare the results to a Sanger sequencing (SS) …

Crystallographic analysis has shown that imatinib binds to and stabilizes an inactive
conformation of ABL, in which the centrally located activation loop is not phosphorylated and …